GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jeil Pharma Holdings Inc (XKRX:002620) » Definitions » Debt-to-Equity

Jeil Pharma Holdings (XKRX:002620) Debt-to-Equity : 0.50 (As of Dec. 2023)


View and export this data going back to 1988. Start your Free Trial

What is Jeil Pharma Holdings Debt-to-Equity?

Jeil Pharma Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩147,537 Mil. Jeil Pharma Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩11,698 Mil. Jeil Pharma Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩319,461 Mil. Jeil Pharma Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.50.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Jeil Pharma Holdings's Debt-to-Equity or its related term are showing as below:

XKRX:002620' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.26   Max: 0.5
Current: 0.5

During the past 13 years, the highest Debt-to-Equity Ratio of Jeil Pharma Holdings was 0.50. The lowest was 0.00. And the median was 0.26.

XKRX:002620's Debt-to-Equity is ranked worse than
65.89% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XKRX:002620: 0.50

Jeil Pharma Holdings Debt-to-Equity Historical Data

The historical data trend for Jeil Pharma Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeil Pharma Holdings Debt-to-Equity Chart

Jeil Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.37 0.28 0.40 0.50

Jeil Pharma Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.42 0.46 0.49 0.50

Competitive Comparison of Jeil Pharma Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Jeil Pharma Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jeil Pharma Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jeil Pharma Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Jeil Pharma Holdings's Debt-to-Equity falls into.



Jeil Pharma Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Jeil Pharma Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Jeil Pharma Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeil Pharma Holdings  (XKRX:002620) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Jeil Pharma Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Jeil Pharma Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Jeil Pharma Holdings (XKRX:002620) Business Description

Traded in Other Exchanges
N/A
Address
745-5, Banpo-dong, Seocho-gu, Seoul, KOR, 137-810
Jeil Pharma Holdings Inc is involved in manufacture and distribution of pharmaceutical products. The company mainly produces finished pharmaceutical products and active pharmaceutical ingredients. It has categorized its products in Antibiotic, Oncology, Cardiovascular, Gastrointestinal, Urology, Respiratory etc. The firm's manufacturing facility and research and development institute located at Yongin-si, Gyeonggi-do in Korea.

Jeil Pharma Holdings (XKRX:002620) Headlines

No Headlines